Respiratory depression is a therapy-limiting side-effect of opioid analgesics, yet our 41 understanding of the brain circuits mediating this potentially lethal outcome remains incomplete. 42
While opioids remain the most powerful tool available for treating moderate to severe pain, 65 their utility is limited by side-effects, especially potentially lethal respiratory depression. Given 66 this risk and the low therapeutic index for many opioids, clinicians often under-treat pain 67 (Nickerson and Attaran 2012; Webster et al. 2011) . Despite the clinical and social significance 68 of opioid-induced respiratory depression, the underlying neural mechanisms and circuits are still 69 not fully understood. 70
In contrast to respiratory depression, the analgesic actions of opioids have been studied 71 intensely, and we now know that these agents produce pain relief by engaging an endogenous 72 brainstem pain modulatory system. This system is the driving force behind the natural 73 heart rate, and body temperature. In the improgan experiments, activity of an RVM neuron was 180 also recorded as described above. A 15-min baseline was established followed by microinjection 181 of drug or vehicle (injected over five to ten minutes, beginning immediately after the last 182 baseline TF). TF, respiratory measurements, heart rate, rectal temperature, and cell activity (in 183 the improgan experiments) were recorded for the next hour. 184
In the third set of experiments, we microinjected either the GABA A For injection of dermorphin-A594 into the RVM, animals were initially anesthetized using 206 5% isoflurane for placement of a jugular catheter, and the anesthetic then switched from inhaled 207 isoflurane to intravenous methohexital (30 -60 mg /hr). After achieving a stable baseline for at 208 least 25 minutes, dermorphin-A594 was injected into the RVM. In some experiments, 45 209 minutes prior to the injection of dermorphin-A594, an injection of the irreversible mu-opioid 210 antagonist, β-funaltrexamine (β-FNA, 300 nl, 6 nmol, Tocris Bioscience), was injected into the 211 RVM. Heart rate, respiratory rate, and rectal temperature were measured as described above. 212
Nociceptive threshold was measured by placing a Peltier device on the left hindpaw, slowly 213 increasing temperature from 35 to 53 °C, and noting the temperate at which a withdrawal was 214 initiated. EMG recordings from the left calf were used to determine the beginning of the 215 withdrawal. Antinociception is expressed as percent of maximum possible effect (%MPE). 216
These experiments allowed a comparison of the analgesic efficacy and respiratory and autonomic 217 depressive effects of dermorphin-A594 with those of DAMGO and improgan. 218 10 Physiological and nociceptive parameters were monitored before and after injection of 219 dermorphin-A594. Sixty minutes after injection, animals were overdosed with methohexital and 220 perfused transcardially with solutions of physiological saline and of 10% formalin. The brains 221 were removed, fixed overnight in 10% formalin, and sectioned at 60 µm using a cryostat. 222
Sections were mounted on glass slides with permount, visualized on an Olympus BX51 223 fluorescent microscope (Olympus, Center Valley, PA), and photographed using a Microfire A/R 224 camera attachment (Optronics, Inc., Goleta, CA). 
Statistical analysis 234
All data are represented as mean + SEM. Drug effects on TF latency, hindpaw withdrawal 235 threshold, respiratory rate, heart rate, and rectal temperature were determined using one-or two-236 way ANOVA, with post-hoc comparisons used where indicated. Differences in mean RVM 237 fluorescence between treatment groups and the effects of dermorphin-A594 relative to baseline 238 were analyzed using unpaired and paired t-tests, respectively. Respiratory amplitude was 239 analyzed using a Friedman's analysis of variance by rank. RVM neurons exhibit a wide range of 240 basal firing rates. A within-cell analysis approach was therefore used in which cell firing data 241 11 post-treatment were compared to baseline using a Wilcoxon's signed ranks test for matched 242 samples. Analyses were performed using GraphPad Prism or Statview. P < 0.05 was considered 243 statistically significant. 244 245 12
RESULTS

246
The RVM contributes to antinociceptive and respiratory-depressant actions of systemically 247 administered morphine. 248
The RVM is defined functionally, as the area where low-current electrical stimulation 249 produces behavioral antinociception, and includes the nucleus raphe magnus and adjacent 250 reticular formation at the level of the facial nucleus (Fields and Heinricher 1985). We first 251 determined whether this region is required for respiratory depressant actions of systemically 252 administered morphine, as well as for analgesia. Respiratory parameters (rate and amplitude) 253
were measured in parallel with the TF response evoked by noxious radiant heat. The latter is an 254 index of nociception widely employed in awake behaving animals that can also be used in lightly 255 anesthetized subjects (Fields and Heinricher 1985) . we recorded nociception, respiration, heart rate, and body temperature simultaneously before and 303 after microinjection of the two agents. We also recorded RVM neuronal activity in the improgan 304 experiments, but not in the DAMGO experiments, since the effect of local DAMGO injection on 305 activity of RVM neurons has been defined previously (Heinricher et al. 1994) . 306
Microinjections of DAMGO or improgan in the RVM at sites shown in Figure 3 produced 307 potent antinociception. TF latency was increased significantly by both agents, but not by vehicle 308 (Figure 4) . The peak antinociceptive effects of improgan and DAMGO were seen at 10-20 and 309 35-45 min post-injection, respectively, consistent with the known time-courses of these agents. 310
Injections of improgan in areas surrounding the RVM, mostly dorsal and rostral (see Figure 3 ) 311 resulted in a small, but statistically significant, increase in TF latency (1.8 ± 0.5 s, n = 23, 312 p < 0.01). 313 15 Although both DAMGO and improgan produced antinociception when microinjected into the 314 RVM, only DAMGO produced a significant respiratory depression, decreasing both respiratory 315 rate and amplitude (Figure 4) . In marked contrast, improgan in the RVM stimulated both 316 respiratory rate and amplitude. The peak effects of improgan and DAMGO were seen at 10-20 317 and 35-45 min post-injection, respectively, for both rate and amplitude. Vehicle injection had no 318 effect on respiration, and injections of improgan in areas surrounding the RVM produced only a 319 modest increase in respiration (4.8 ± 0.18 breaths/min, p < 0.05). These data demonstrate that 320 the analgesic actions of drugs in the RVM are not inextricably linked to respiratory depression. 321
Effects of DAMGO and improgan on heart rate and body temperature are also distinct 322 DAMGO microinjection resulted in a decrease in heart rate while improgan induced a 323 substantial increase (Figure 4 ). Peak effects on heart rate were evident at 10-20 min and 35-45 324 min post-injection with improgan and DAMGO, respectively. A small but statistically 325 significant decrease in heart rate (6.0 ± 2.0 beats/min) was seen in vehicle-treated controls over 326 the course of the experiment. Injections of improgan in areas surrounding the RVM produced a 327 statistically significant increase in heart rate (25 ± 6.6 beats/min, p < 0.01). 328
Like heart rate, body temperature was also differentially affected by DAMGO and improgan. 329 DAMGO microinjection decreased, whereas improgan increased, body temperature (Figure 4) . 330
The peak effects of improgan and DAMGO on temperature were seen at 35-45 min post-331 injection. The delayed time-course for improgan in this case presumably reflects the kinetics of 332 whole-body temperature change. Injections of improgan in areas surrounding the RVM 333 produced a small but statistically significant increase in body temperature (0.1 ± 0.03 °C, 334 p < 0.01). respiratory rate, respiratory amplitude, heart rate, and body temperature. Improgan 832 and DAMGO were injected over a period of 5 to 10 min immediately following a 15-833 min baseline (BL, average of three trials). 834
There were no differences among groups in any of these parameters in baseline (one-835 way between-groups ANOVA, 10 -36 animals/group). *p < 0.05, **p < 0.01, 836 ***p < 0.001 compared to pre-injection baseline using repeated-measures ANOVA 837 followed by Dunnett's test (respiratory rate, heart rate, body temperature) or 838
Friedman's analysis of variance by ranks followed by a Dunn's test (respiratory 839 amplitude). 840 b. Group data confirm that all three RVM cell classes exhibit an increase in firing 847 rate following improgan, but not vehicle, microinjection. 6-8 cells/group, *p < 0.05 848 compared to pre-injection baseline, Wilcoxon's signed-ranks test. 849 Figure 6 Effects of RVM improgan and DAMGO, compared to bicuculline and muscimol. TF 850 latency (expressed as percent maximum possible effect, %MPE), change in 851 respiratory rate, change in heart rate, and change in body temperature. Each data set 852 was analyzed using an ANOVA followed by a Dunnett's test for comparison to aCSF 853 vehicle control. 9 -36 animals/group, **p < 0.01, ***p < 0.001 compared to aCSF 854 group. 855
